Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide
The study tested 25mg and 50mg doses, and both showed a higher efficacy after 52 weeks compared to 14mg.
By Marketwire, translated by katrine gøthler
Novo Nordisk has reached its endpoint in a phase IIIb trial called Pioneer Plus, in which the efficacy and safety of once-daily oral semaglutide in 25mg and 50mg doses were tested.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
